Biopharma conference takeaways Report Interpretation

Overview

This conference-takeaway report reviews presentations by ARVN, GPCR, NRIX and PRME at Morgan Stanley's 2026 Global Healthcare Conference. It concentrates on each company's clinical pipeline, expected data cadence, regulatory discussions, strategic partnerships and competitive positioning rather than issuing a report-wide investment recommendation.

Core views

ARVN discussed a strategy of retaining programs it considers appropriate to own while partnering other assets. For ARV-393, its BCL6 degrader in non-Hodgkin lymphoma, near-term disclosure is expected to emphasize safety, pharmacokinetics and pharmacodynamics in predominantly T-cell lymphoma/AITL patients; management indicated an approximately 40% objective-response-rate bar. Data from LBCL/DLBCL monotherapy and the first Columvi/glofitamab combination are expected around mid-2027, while management did not provide a performance threshold for the LBCL cut. Commercial positioning was described as late-line monotherapy in 3L/4L DLBCL and 2L+ AITL, with combinations intended to move treatment into earlier lines. Management believes the market can support multiple competitors, with development speed and breadth of combination options as key differentiators. For ARV-102, the LRRK2 degrader in PSP/PD, ARVN plans to present ocular-motor improvement and further biomarkers at the October MDS congress. The program remains subject to follow-up FDA questions related to a clinical hold; management expects to update investors after agency discussions conclude over the next several months but provided no resolution timetable. The company is simultaneously engaging US, European and Japanese regulators to potentially harmonize a global PSP plan, while retaining flexibility between a Phase 1b followed by registrational-trial sequence and a single combined trial. ARV-027 in SBMA/Kennedy's has completed Phase 1 single-ascending-dose cohorts and begun multiple-ascending-dose dosing, with first data expected in 1H27. Management cited roughly 50% skeletal-muscle degradation as a benchmark, based on mouse evidence of full recovery to wild-type endurance at that level. GPCR's obesity presentation centered on oral GLP-1 aleniglipron and oral amylin ACCG-2671. Management said competing oral GLP-1 products had already reached approximately 17% market share, with around 80% of users new to the class, only months after launch, and could reach about 50% by 2030. GPCR views aleniglipron's 2.5–180mg dynamic dose range as a potential best-in-class differentiator. In the Phase 2 LINK study, the top dose produced up to 16% weight loss after a median roughly 7–8 weeks, with no observed plateau; management expects further weight loss at 52 weeks in Phase 3. ACCOMPLISH-1 in overweight patients and ACCOMPLISH-2 in overweight patients with type 2 diabetes will enroll approximately 5,000 patients across 45mg, 90mg and 180mg doses, titrated every four weeks from 2.5mg, with topline results expected in 2H28. The report also highlights the limits of the early GPCR data. The 2.6% adverse-event-driven discontinuation rate was lower than competitors', but management noted that the study was small and short, so Phase 3 discontinuation could be higher. Three Phase 2 readouts are due in 4Q26: body-composition data separating fat from muscle, a type 2 diabetes cohort dosed up to 180mg, and a switch study from injectable GLP-1 therapy. The switch study will test whether the observed 16% weight loss can be maintained or extended after injectable therapy; the starting treatment, including semaglutide versus tirzepatide, may materially affect comparability. ACCG-2671 showed a six-day half-life in Phase 1 single-ascending-dose testing, supporting exploration of daily and weekly dosing. A 12-week Phase 2a multiple-ascending-dose study is enrolling, with data expected in 1H27, while an oral GLP-1-plus-amylin combination trial is planned for 4Q26 with likely data in 2H27. Management also cited intellectual-property protection into the 2040s and ongoing strategic-partnership dialogue. NRIX focused on development acceleration following its Roche collaboration for bexdeg. The deal includes $700 million upfront and up to $2.3 billion in total milestones, 40/60 development-cost sharing, a 50/50 US profit share and ex-US royalties. Near-term work is intended to accelerate autoimmune indications, including a CSU trial planned with Roche's Xolair team. In CLL, the Phase 3 DAYBreak CLL-306 study compares bexdeg head-to-head with Lilly's Jaypirca in approximately 600 all-comer second-line patients previously exposed to a covalent BTK inhibitor. ORR and PFS are dual primary endpoints. Management's mechanistic case is that the degrader can address post-cBTKi resistance mutations not addressed by Jaypirca and remove BTK's scaffolding function; it noted that approximately 40% of resistant patients carry a BTK mutation. However, the event-driven study has no disclosed superiority assumption or timeline beyond first patient enrollment. For later-line CLL, NRIX confirmed that the single-arm DAYBreak CLL-201 will enroll approximately 100 patients after covalent BTKi, BCL-2 inhibitor and non-covalent BTKi treatment, aiming to support potential accelerated approval. Phase 1 benchmarks cited were 65–80% ORR in later-line cohorts and 22.1-month PFS. Differentiation against BeOne's BGB-16673 remains unresolved because both programs have been in an approximately 80% ORR range; NRIX expects potential separation to depend on safety and its molecule's selectivity. The company reiterated ASH in December 2026 and EHA in June 2027 as potential update venues. It also plans a Phase 1b/2 combination study with Roche's Venclexta to enable fixed-duration regimens, although the frontline monotherapy-versus-combination approach remains under discussion. NRIX additionally described expansion into autoimmune, neurology and partnered degrader programs. It has completed more than 200 healthy volunteers in the new autoimmune setting, plans to file a CSU IND in 2026 and then proceed directly to Phase 2, with multiple sclerosis following in 2027. Management expects lower doses than the 600mg once-daily oncology regimen for immunology and neurology. For the Sanofi STAT6 program, NRIX's opt-in decision depends on receiving a clinical report that includes atopic-dermatitis patient data; Phase 1 is expected to conclude in 2027 before Phase 2. For Gilead's IRAK4 program, management expects Phase 1 completion by year-end and a transition to Phase 2, and believes stopped competing programs have improved its positioning, although clinical validation remains ahead. PRME's presentation stressed delivery and regulatory progress for its gene-editing programs. Management views liver delivery as effectively solved and the eye and ear as tractable, while framing the brain as the largest future unlock. For PM577a in Wilson's disease, the global Phase 1/2 dose-escalation study will initially include three dose cohorts and measure safety, tolerability, radiolabeled copper PET, ceruloplasmin and urinary copper. Management's base case for a possible registrational endpoint is taking patients off standard of care for a period, while the suitability of copper PET as an accelerated-approval surrogate remains dependent on data strength and FDA flexibility. Initial proof-of-concept data in 2027 are expected from roughly 6–12 patients and should include safety and the three copper-metabolism markers. For PM647 in AATD, PRME reiterated a 3Q26 IND target and initial proof-of-concept data in 2027; serum AAT levels and the M-versus-Z percentage may be measurable one to two weeks after dosing. Management acknowledged competitor base-editing data showing mid-teens systemic AAT levels and approaching saturation, but argued that restoration of wild-type protein without bystander edits could support best-in-class potential. For PM359 in CGD, PRME is planning an FDA submission in 1H27, contingent only on small CMC requirements, based on an FDA-aligned two-patient dataset. Management views CGD as a small commercial opportunity that could be addressed with limited incremental spending.

Analysis framework

Morgan Stanley organizes the conference discussions company by company, reviewing management's pipeline updates, clinical-study designs and endpoints, reported efficacy or safety observations, regulatory interactions, partnership structures, competitive comparators and forthcoming catalysts. The report uses management-provided benchmarks and peer comparisons to explain how each program may differentiate, while preserving the uncertainty around unreported data, regulatory outcomes and trial timing.

Methodology notes

• Event-Driven and Behavioral FinanceEvent-driven analysis

  Clinical, regulatory and conference-catalyst analysis

  The report evaluates upcoming trial readouts, conference presentations, IND filings, FDA discussions and partnership milestones as events that may clarify the development outlook for each program.

• Other

  Clinical trial and competitive benchmarking

  Management commentary is assessed against response-rate, progression-free-survival, weight-loss, adverse-event and biomarker benchmarks, as well as named competing treatments and development programs.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• ARVN

  Covered company with oncology and neurology protein-degrader programs.

  Strengths

  Multiple programs with defined 2027 data milestones and a potential combination path into earlier oncology treatment lines.

  Weaknesses

  ARV-102 remains under FDA clinical-hold follow-up, and key development design decisions remain open.

  Comparison

  Management expects competition to depend on development speed and breadth of combinability.

  Risks

  Clinical response, regulatory-hold resolution and global PSP development plans remain uncertain.

• GPCR

  Covered company developing oral GLP-1 and oral amylin obesity therapies.

  Strengths

  Aleniglipron produced up to 16% weight loss in Phase 2; its broad dose range and oral formulation are presented as differentiators.

  Weaknesses

  The initial adverse-event discontinuation evidence came from a small, short study.

  Comparison

  The report references competing oral GLP-1 products, Lilly's maintenance study, ZEAL's petrelintide and Novo's cagrilintide.

  Risks

  Phase 3 efficacy, tolerability, body-composition outcomes and performance after switching from injectables remain to be established.

• NRIX

  Covered company developing bexdeg and partnered degrader programs.

  Strengths

  The Roche collaboration provides major upfront funding, cost sharing and commercialization economics; bexdeg is positioned against resistance mutations and BTK scaffolding.

  Weaknesses

  The Phase 3 superiority case, timing and differentiation from BGB-16673 have not been established.

  Comparison

  Bexdeg is being studied against Jaypirca, while management cited an approximately 80% ORR range for both bexdeg and BeOne's BGB-16673.

  Risks

  Clinical differentiation, safety advantage, event-driven trial timing and partnered-program execution remain uncertain.

• PRME

  Covered company developing gene-editing programs for Wilson's disease, AATD and CGD.

  Strengths

  Management sees liver delivery as solved, cites a supportive FDA backdrop and expects early biomarker readouts shortly after AATD dosing.

  Weaknesses

  Brain delivery remains a future challenge, and early clinical datasets will be small.

  Comparison

  Management cited competitor base-editing programs with mid-teens systemic AAT and near-saturation results.

  Risks

  Regulatory endpoints, accelerated-approval surrogate acceptance, clinical biomarker consistency and proof of wild-type protein restoration remain unproven.

Key data

• ARV-393 near-term ORR benchmark~40%Management's stated bar for the near-term safety/PK/PD-focused release in predominantly T-cell lymphoma patients.
• ARV-027 first data1H27Expected after Phase 1 SAD completion and initiation of MAD dosing in SBMA/Kennedy's disease.
• Aleniglipron Phase 2 weight lossUp to 16%Observed after a median ~7–8 weeks on the top dose in LINK; no plateau was observed.
• Aleniglipron Phase 3 enrollment~5,000 patientsCombined ACCOMPLISH-1 and ACCOMPLISH-2 enrollment at 45/90/180mg; topline expected in 2H28.
• Aleniglipron AE-driven discontinuation2.6%Management said this was lower than competitors', while cautioning that the initial study was small and short.
• ACCG-2671 half-life6 daysPhase 1 SAD result supporting exploration of daily and weekly dosing.
• Roche-NRIX bexdeg collaboration$700mn upfront; up to $2.3bn totalIncludes 40/60 development-cost sharing, a US 50/50 profit share and ex-US royalties.
• DAYBreak CLL-306 enrollment~600 patientsEvent-driven Phase 3 study versus Jaypirca with ORR and PFS as dual primary endpoints.
• PRME Wilson's disease initial POC~6–12 patients in 2027Expected to include safety plus radiolabeled copper PET, ceruloplasmin and urinary-copper data.

Impact & implications

The report indicates that the companies' near- and medium-term narratives depend chiefly on clinical proof points and regulatory execution. ARVN must resolve regulatory and clinical-development questions; GPCR must validate early obesity data in larger studies; NRIX must demonstrate meaningful efficacy and safety differentiation across oncology and autoimmune programs; and PRME must translate delivery and biomarker progress into credible clinical proof of concept.

Risks

• ARVN's FDA clinical-hold follow-up has no disclosed resolution date, and key PSP trial-design choices remain open.
• GPCR cautioned that its 2.6% adverse-event discontinuation rate may rise in Phase 3 because the earlier study was small and short.
• NRIX has not disclosed superiority assumptions or a timeline for its event-driven CLL Phase 3 trial, and differentiation from BGB-16673 remains undetermined.
• PRME's potential registrational path and use of copper PET as an accelerated-approval surrogate depend on data strength and FDA flexibility.

What to watch

• ARVN's October MDS presentation, ARV-027 first data in 1H27, and mid-2027 ARV-393 data and combination readout.
• GPCR's three Phase 2 obesity readouts in 4Q26, ACCG-2671 Phase 2a data in 1H27, and oral-combination data likely in 2H27.
• NRIX's CSU IND filing in 2026, potential ASH 2026 and EHA 2027 CLL/NHL updates, and progress of the Venclexta combination study.
• PRME's 3Q26 AATD IND filing, 2027 Wilson's disease and AATD proof-of-concept data, and its planned 1H27 CGD FDA submission.